<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1727-897X</journal-id>
<journal-title><![CDATA[MediSur]]></journal-title>
<abbrev-journal-title><![CDATA[Medisur]]></abbrev-journal-title>
<issn>1727-897X</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Cienfuegos, Centro Provincial de Ciencias Médicas, Provincia de Cienfuegos.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1727-897X2022000300478</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Subtipos inmunohistoquímicos y su relación con los aspectos clínico-patológicos e histológicos del cáncer de mama]]></article-title>
<article-title xml:lang="en"><![CDATA[Immunohistochemical subtypes and their relationship with the clinicopathological and histological aspects of breast cancer]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Longoria Boada]]></surname>
<given-names><![CDATA[Lourdes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A4"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González Pardo]]></surname>
<given-names><![CDATA[Secundino]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Muñoz]]></surname>
<given-names><![CDATA[Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Facultad de Ciencias de la Salud Enrique Ortega Moreira. Universidad de Especialidades Espíritu Santo  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Ecuador</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Facultad de Ciencias de la Salud. Universidad Técnica del Norte  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Ecuador</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Facultad de Salud Pública. Universidad Camilo José Cela  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Abel Gilbert Pontón  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>20</volume>
<numero>3</numero>
<fpage>478</fpage>
<lpage>486</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1727-897X2022000300478&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1727-897X2022000300478&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1727-897X2022000300478&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Fundamento: el pronóstico y la terapéutica del cáncer de mama están estrechamente relacionados con las características histopatológicas del paciente. Estas permiten establecer grupos pronósticos, como apoyo en la decisión de tratamientos individuales efectivos. Sin embargo, la información existente sobre la relación entre estos aspectos y los subtipos inmunohistoquímicos de cáncer de mama es limitada en países latinoamericanos.  Objetivo:  determinar la relación entre las características clínico-patológicas e histológicas y los subtipos inmunohistoquímicos de cáncer de mama en pacientes ecuatorianas. Métodos: estudio observacional de corte transversal en pacientes ecuatorianas atendidas en el Hospital Abel Gilbert Pontón entre enero de 2014 y diciembre de 2017. Se incluyeron 199 pacientes con diagnóstico histopatológico de cáncer de mama. Se analizaron variables clínico-patológicas: edad, tamaño del tumor y estado de los ganglios linfáticos; histológicas: tipo y grado histológico.  Resultados: la edad media de los pacientes fue de 56,77 ± 11,96 años. Se observaron metástasis ganglionares en la mayoría de los casos (63,3 %). El tamaño medio del tumor fue de 3,88 ± 1,61 cm. Más de la mitad de los casos (56,8 %) presentaron un grado histológico moderadamente diferenciado. El subtipo molecular predominante fue la neoplasia luminal A (53,8 %). El análisis demostró una asociación significativa (p &lt;0,0001) entre subtipos inmunohistoquímicos y las características clínico-patológicas e histológicas del cáncer de mama.  Conclusiones: la neoplasia mamaria en las pacientes ecuatorianas se diagnostica en estadios avanzados. El estudio enfatiza en la necesidad de introducir las pruebas de receptores inmunohistoquímicos en la práctica clínica para ayudar y determinar la biología del cáncer de mama, mejorar el efecto sobre la terapia y el pronóstico del paciente.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Background:  The prognosis and therapy of breast cancer (BC) is closely related to the histopathological characteristics of the patient. These allow to establish prognostic groups, as support in the decision of effective individual treatments. However, the existing information is limited on the relationship between these aspects and the immunohistochemical subtypes (IHC) of breast cancer in Latin American countries.  Objective:  To determine the relationship between the clinical-pathological and histological characteristics with the IHC subtypes of BC in Ecuadorian patients.  Methods:  An observational of the cross-sectional study was carried out in Ecuadorian patients treated at the Abel Gilbert Pontón Hospital between January 2014 and December 2017. 199 patients with a histopathological diagnosis of BC were included. Clinicopathological variables were analyzed: age, tumor size and lymph node status; histological: type and histological grade.  Results:  The mean age of the patients was 56,77 ± 11,96 years. Lymph node metastases were observed in most cases (63,3%). The mean tumor size was 3,88 ± 1,61 cm. More than half of the cases (56,8%) presented a moderately differentiated histological grade. The predominant molecular subtype was Luminal A neoplasia (53,8%). The analysis showed a significant association (p &lt;0, 0001) between IHC subtypes and the clinicopathological and histological characteristics of BC.  Conclusions:  Breast neoplasia in Ecuadorian patients is diagnosed in advanced stages. The study emphasizes the need to introduce IHC receptor tests into clinical practice to help determine the biology of breast cancer, improve the effect on therapy and the patient's prognosis.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[cáncer de mama, biomarcadores, inmunohistoquímica]]></kwd>
<kwd lng="es"><![CDATA[pronóstico]]></kwd>
<kwd lng="en"><![CDATA[breast cancer]]></kwd>
<kwd lng="en"><![CDATA[biomarkers]]></kwd>
<kwd lng="en"><![CDATA[immunohistochemistry]]></kwd>
<kwd lng="en"><![CDATA[prognosis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Cáncer de mama]]></source>
<year>2021</year>
<publisher-loc><![CDATA[Washington ]]></publisher-loc>
<publisher-name><![CDATA[OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peñate]]></surname>
<given-names><![CDATA[FD]]></given-names>
</name>
<name>
<surname><![CDATA[de la Torre]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El autoexamen y la detección precoz del cáncer de mama]]></article-title>
<source><![CDATA[Medicentro Electrónica]]></source>
<year>2018</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yanagawa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ikemot]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kawauchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Furuya]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yamamoto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Oka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype]]></article-title>
<source><![CDATA[BMC Research Notes]]></source>
<year>2012</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Da Silva]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dittrich]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tecnologia em arteterapia para à saúde de pessoas com cancer de mama]]></article-title>
<source><![CDATA[Saúde &amp; Transformação Social/Health &amp; Social Change]]></source>
<year>2014</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>10-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coates]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Winer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Goldhirsch]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gnant]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Piccart-Gebhart]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tailoring therapies-improving the management of early breast cancer St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015]]></article-title>
<source><![CDATA[Annals Oncology]]></source>
<year>2015</year>
<volume>26</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1533-46</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Subik]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Baxter]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Strzepek]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Costello]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Crowley]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines]]></article-title>
<source><![CDATA[Breast Cancer (Auckl)]]></source>
<year>2010</year>
<volume>4</volume>
<page-range>35-41</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osorio]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bello]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vega]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores de riesgo asociados al cáncer de mama]]></article-title>
<source><![CDATA[Revista Cubana de Medicina General Integral]]></source>
<year>2020</year>
<volume>36</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Socorro]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunohistoquímica en el cáncer de mama. Herramienta necesaria en la actualidad]]></article-title>
<source><![CDATA[Medisur]]></source>
<year>2018</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sohn]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Seo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunohistochemical Subtypes of Breast Cancer Correlation with Clinicopathological and Radiological Factors]]></article-title>
<source><![CDATA[Iran J Radiol]]></source>
<year>2016</year>
<volume>13</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Widodo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Dwianingsih]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Anwar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Triningsih]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Utoro]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Aryandono]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic Value of Clinicopathological Factors for Indonesian Breast Carcinomas of Different Molecular Subtypes]]></article-title>
<source><![CDATA[Asian Pac J Cancer Prev]]></source>
<year>2017</year>
<volume>18</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1251-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Edge]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Byrd]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Compton]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fritz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Trotti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[AJCC Cancer Staging Manual]]></source>
<year>2010</year>
<edition>7</edition>
<publisher-loc><![CDATA[Chicago ]]></publisher-loc>
<publisher-name><![CDATA[Springer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características clínicas y pronósticas de los subtipos moleculares de cáncer de mama determinados por inmunohistoquímica Arequipa, Perú]]></article-title>
<source><![CDATA[Rev Peru Med Exp Salud Publica]]></source>
<year>2017</year>
<volume>34</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>472-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simón]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bines]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Werutsky]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Soares]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chalu]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Getúlio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil The AMAZONA retrospective cohort study]]></article-title>
<source><![CDATA[The Breast]]></source>
<year>2019</year>
<volume>44</volume>
<page-range>113-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caldarella]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Buzzoni]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Crocetti]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bianchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vezzosi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Apicella]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Invasive breast cancer a significant correlation between histological types and molecular subgroups]]></article-title>
<source><![CDATA[J Cancer Res Clin Oncol]]></source>
<year>2013</year>
<volume>139</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>617-23</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spitale]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzola]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Soldini]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzucchelli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bordon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast cancer classification according to immunohistochemical markers clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland]]></article-title>
<source><![CDATA[Annals Oncology]]></source>
<year>2009</year>
<volume>20</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>628-35</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ulloa]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ronquillo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sobrevida en pacientes con cáncer de mama según su inmunohistoquímica experiencia del Instituto Oncológico Nacional - Sociedad de Lucha Contra el Cáncer, Guayaquil, Ecuador]]></article-title>
<source><![CDATA[Rev Méd Sinerg]]></source>
<year>2020</year>
<volume>5</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vela]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Salazar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Salazar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frecuencia de subtipos moleculares de cáncer de mama, Hospital Metropolitano, 2016-2019, Quito-Ecuador]]></article-title>
<source><![CDATA[Metro Ciencia]]></source>
<year>2020</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>32-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lebert]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lester]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Powell]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Seal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in the systemic treatment of triple-negative breast cancer]]></article-title>
<source><![CDATA[Current Oncology]]></source>
<year>2018</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>142-50</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adani-Ifè]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Amégbor]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Doh]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Darré]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast cancer in togolese women immunohistochemistry subtypes]]></article-title>
<source><![CDATA[BMC Women&amp;apos;s Health]]></source>
<year>2020</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mwakigonja]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lushina]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mwanga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characterization of hormonal receptors and human epidermal growth factor receptor-2 in tissues of women with breast cancer at Muhimbili National Hospital, Dar es salaam, Tanzania]]></article-title>
<source><![CDATA[Infect Agent Cancer]]></source>
<year>2017</year>
<volume>12</volume>
<page-range>60</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Akbar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Akbar]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Naveed]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency and correlation of molecular subtypes of breast cancer with clinicopathological features]]></article-title>
<source><![CDATA[J Ayub Med Coll Abbottabad]]></source>
<year>2014</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>290-3</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sengal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Haj-Mukhtar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Elhaj]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bedri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kantelhardt]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mohamedani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series]]></article-title>
<source><![CDATA[BMC Cancer]]></source>
<year>2017</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
